Balancing Sarepta Therapeutics' Technicals with Its Fundamentals

By Chris Stiles • Tuesday, April 15 09:59 • Permanent Link

Sarepta Therapeutics logged a 2.2% change during today's morning session, and is now trading at a price of $55.84 per share. The S&P 500 index moved 0.0%. SRPT's trading volume is 222,596 compared to the stock's average volume of 1,832,306.

Sarepta Therapeutics trades -63.97% away from its average analyst target price of $155.0 per share. The 24 analysts following the stock have set target prices ranging from $70.0 to $209.0, and on average have given Sarepta Therapeutics a rating of buy.

If you are considering an investment in SRPT, you'll want to know the following:

Sarepta Therapeutics's current price is 104.5% above its Graham number of $27.31, which implies that at its current valuation it does not offer a margin of safety
Sarepta Therapeutics has moved -53.4% over the last year, and the S&P 500 logged a change of 7.0%
Based on its trailing earnings per share of 2.34, Sarepta Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 23.9 while the S&P 500 average is 29.3
SRPT has a forward P/E ratio of 4.9 based on its forward 12 month price to earnings (EPS) of $11.45 per share
Its Price to Book (P/B) ratio is 3.54 compared to its sector average of 3.53
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
Based in Cambridge, the company has 1,372 full time employees and a market cap of $5.42 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.